<DOC>
	<DOCNO>NCT00915746</DOCNO>
	<brief_summary>This open-label ( physician healthy volunteer know treatment administer ) study assess pharmacokinetics ( process JNJ-31001074 absorbed , distribute , metabolize , eliminate body ) JNJ-31001074 take alone combination ketoconazole . The study consist three phase : screening phase determine eligibility , open-label treatment phase consist three period end-of study/early withdrawal assessment phase .</brief_summary>
	<brief_title>A Drug Interaction Study JNJ-31001074 Ketoconazole Healthy Volunteers</brief_title>
	<detailed_description>This open-label ( physician healthy volunteer know treatment administer ) , sequential design ( one ) study assess pharmacokinetics ( process JNJ-31001074 absorbed , distribute , metabolize , eliminate body ) JNJ-31001074 take alone combination ketoconazole . The study consist three phase : screening phase determine eligibility , open-label treatment phase consist three period end-of-study/early withdrawal assessment phase . During screen phase , healthy volunteer evaluate see meet selection criterion specify protocol . Healthy volunteer meet criterion report study center Day -1 . Volunteers admit study center fast ( food beverage ) overnight least 10 hour . Volunteers remain study center 11 day . The open-label treatment phase consist three period . In Period 1 , single-dose JNJ-31001074 10 mg administer Day 1 , follow three day multiple blood sampling ( Days 1-3 ) . In Period 2 ( Days 4-6 ) , 400 mg ketoconazole administer day prior predose blood sample take . In Period 3 ( Days 7-11 ) , JNJ-31001074 10 mg ketoconazole 400 mg administer together Day 7 , follow four day multiple blood sample . Ketoconazole also administer Day 8 Day 9 Period 3 . No study drug administer Days 2 3 Period 1 , Days 10 11 Period 3 . The end-of-study phase assessment perform completion four day blood sample Day 11 . Safety tolerability assess throughout volunteer 's participation . Volunteers instruct report adverse event occur 30 day last dose study drug . The maximum study duration volunteer expect 32 day . JNJ-31001074 10 mg administer orally Days 1 7 ; ketoconazole 400 mg administer orally Days 4 , 5 , 6 , 7 , 8 , 9 .</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>healthy volunteer age 1855 woman , must non childbearing potential ( ie , post menopausal surgically sterile ) negative pregnancy test body mass index 1830 body weight great equal 50 kilogram blood pressure 90 140 mgHg systolic high 90 mgHg diastolic nonsmoker History current clinically significant medical illness clinically significant abnormal laboratory value ( ) clinically significant abnormal physical examination , vital sign electrocardiogram pregnant , lactate complete last term pregnancy within six month screen use prescription non prescription medication except paracetamol ( acetaminophen/TYLENOL ) , bisphosphonates ( drug treat osteoporosis ) , hormone replacement therapy within 14 day first dose study medication history drug alcohol abuse history smoking use nicotinecontaining substance within previous two month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>ketoconazole</keyword>
	<keyword>CYP3A4 inhibitor</keyword>
	<keyword>drug interaction</keyword>
	<keyword>metabolism</keyword>
	<keyword>Healthly Volunteer</keyword>
	<keyword>JNJ-31001074</keyword>
</DOC>